Featured tickers: $ACAD $ACHN $ACRX $ACT $AEGR $AET $AEZS $AGIO $ASPX $AVNR $BIOL $BLUE $BMY $CEMP $CLDX $CLVS $CYNAF $DEPO $EPZM $FMI $GNVC $HUM $ICPT $MOH $MRK $NYMX $OXGN $RMTI $RPRX $SLXP $SRPT $TARO $UNH $WLP
Note you can use the search box at the upper right to find all BiotechDueDiligence content related to a particular stock of interest.
Rozen (Broad) answering how did you know crispr was hot? Within 24 hours of first paper had 30+ MTA requests. #BEU14
— Laura Strong (@scientre) November 3, 2014 Looks like $NYMX CEO has patiently built quite a retail following over the years all of which got screwed royally today
— BiotechSage (@BiotechSage) November 3, 2014 $ACHN shouldn't have taken this long unless they're increasing dose
— Vikram Khanna (@VikramKhanna_) November 4, 2014 I have joined the @YahooFinance Contributors team. My new Tumblr launched today —> http://t.co/sOmiGypoDH Thx to @ppearlman for invite.
— Adam Feuerstein (@adamfeuerstein) November 4, 2014 $ACHN data later this Q, may provide an opportunity for the runup
— Amit Gupta (@amitp_gupta) November 4, 2014 Interested to see what happens to health insurance stocks today. $AET $MOH $WLP $UNH $HUM
— Matthew Herper (@matthewherper) November 5, 2014 Things I don't hear every day: Your program is a bit too late stage for us.
— Laura Strong (@scientre) November 4, 2014 B Saunders - "There are deals sometimes where people don't matter" $ACT
— Tyler (@tylerhcarter) November 5, 2014 Prediction: $FMI will sell off if no raise guid4 2014 tests performed.Simple arithmetic:Leaving 2014 guid unchgd-->weak test numbers4 4Q14.
— Roy Friedman (@DewDiligence) November 5, 2014 Gotta love how $gnvc is double dipping on this $3M. Issued same pr last week
— NathanAaron (@NathanAhron) November 5, 2014 I am unreasonably excited it is conference season again. Looking forward to seeing all my Biotweep friends over the coming months.
— David Miller (@AlpineBV_Miller) November 5, 2014 my best trade of the last 18 months ? selling $CLDX in the 30s
— Dan Rosenblum (@sharkbiotech) November 5, 2014 .@bradloncar @AdamSinger According to $FMI CC, 1other large multinational co covers Foundation1 for employees,but FMI can't disclose who.
— Roy Friedman (@DewDiligence) November 5, 2014 Ebola patients recovering without need of drugs from overhyped stocks. Fundamentals prevail. Good.
— Juan P. Serrate, DVM (@JPZaragoza1) November 6, 2014 @sport234a First analyst to say "congratulations on the quarter" earns a lifelong ban from the industry.
— Brad Loncar (@bradloncar) November 6, 2014 I am long $CYNAF $ASPX $CEMP on my mid term acct - as for options acct $ACAD $MRK and $BMY - I am watching you @GantosJ :-)
— Alfredo Fontanini (@AF_biotech) November 6, 2014 $DEPO - Heck of a run over the past year, +110%. That's got to get the CEO in @adamfeuerstein best CEO list, or at least honorable mention?
— Jason Napodano, CFA (@JNapodano) November 6, 2014 $biol ceo and directors took down a huge chunk of yesterday's raise. That's how it should be done.
— NathanAaron (@NathanAhron) November 6, 2014 Idea to save billion dollars in healthcare $. Teach docs what is appropriate vs inappropriate inpatient consultations
— daviesbj (@daviesbj) November 5, 2014 .@ashishkjha @lisarosenbaum17 Sure seems like it's hard to deliver 'evidence-based medicine' and 'patient-centered care' simultaneously
— Amitabh Chandra (@amitabhchandra2) November 5, 2014 @bradloncar you should add the $150M mixed shelf & insider sells that occurred in that timeline. Pro tip: you may have to use smaller font;)
— Joe (@Drchik23) November 5, 2014 ACRX PR: transition period; remain confident; resubmission; transformational; positioned for success cc @bradloncar gonna need an addendum )
— Don Shimoda (@zDonShimoda) November 5, 2014 "Aeterna" means eternal. I don't know what "Zentaris" means but I'm guessing "suck." $AEZS
— Adam Feuerstein (@adamfeuerstein) November 6, 2014 — Bio Stocks™ (@BioStocks) November 6, 2014 $aezs really screwed the people looking to get out before the close yesterday. No reason to halt then.
— Festo (@Festo50) November 6, 2014 Why I love #Twitter -I'm getting real time updates from #fda #odac hearing on #Panobinostat #hcsm #mmsm #myeloma http://t.co/CyaW4YIfu6
— Myeloma Teacher (@MyelomaTeacher) November 6, 2014 As a great ex-colleague of mine once said, it's possible for sth to be earnings enhancing and value destroying at the same time $AEGR
— Jacob Plieth (@JacobEPVantage) November 6, 2014 One thing is clear from Drew Pardoll's opening summary at #SITC2014 is that we have more questions than answers. So much yet to learn!
— Sally Church (@MaverickNY) November 6, 2014 — 23aloha (@23aloha) November 7, 2014 Definite optimism: one inspiring abstract after another at #ASH14 this morning, especially in CAR-T. Biotech companies bringing the science.
— David Maizenberg (@biologypartners) November 6, 2014 .@regeneron joined Twitter and its first follow was @SanofiUS, which is kind of endearing.
— Damian Garde (@DamianFierce) November 6, 2014 @23aloha Bio trading is crazy
— DCam (@dcamtrades) November 6, 2014 #SITC2014 has the highest women:men ratio of any conference I've ever been at. Doing something right in immunotherapy.
— David Miller (@AlpineBV_Miller) November 6, 2014 I like the company, but have to say $EPZM data are at best underwhelming. 4/28 in a PoC, genetically defined pop doesn't pass muster
— Vikram Khanna (@VikramKhanna_) November 6, 2014 $SLXP - WON'T ANSWER QUESTIONS ON AUDIT REVIEW - classy...
— Ian Estepan (@ianestepan) November 6, 2014 $SLXP management just said openly that the worst case is the company has lost 6 months worth of revenue. Wow
— Brad Loncar (@bradloncar) November 6, 2014 I've worked trench duty for 2 AdCom panels in my career - one positive and one negative. Requires a fortitude unlike anything I've ever done
— LifeSciGuy (@LifeSciGuy) November 6, 2014 .@TexasDSHS: 21-day monitoring ends Friday Nov 7 for last person in TX connected to 3 #Ebola cases, Duncan, Pham & Vinson #CDC #WHO
— Donna Young (@ScripDonnaDC) November 6, 2014 @sport234a Was this the busiest day ever? Big earnings day, ASH abstracts, $4.5B M&A deal, a multi-billion scandal, an AdCom, anything else?
— Brad Loncar (@bradloncar) November 6, 2014 @BiotechMoney18 If traders purely based on twitter sentiment, they could have long $AEZS and short $RMTI, making them big fat losers, LOL!
— Ethan28 (@Ethane28) November 6, 2014 @23aloha biotech I find you have to be able to be agile until you find a winner. But the winner if you keep adding tends to make up for all.
— Adam Singer (@AdamSinger) November 6, 2014 — 23aloha (@23aloha) November 7, 2014 @DewDiligence @Sport234a Betcha $AGN was the one who recognized $SLXP's inventories were so off.
— Brad Loncar (@bradloncar) November 7, 2014 Holy fuck, more news tonight?!?!? $ICPT. Send bourbon now!!
— Adam Feuerstein (@adamfeuerstein) November 7, 2014 @bosbizdon Now we know one reason why they were poaching $SRPT employees.
— Brad Loncar (@bradloncar) November 7, 2014 LOL nice $ICPT pun -> RT @Sport234a: "Debilitating Itchiness" is all you need to know for tmrw...
— Andy Biotech (@AndyBiotech) November 7, 2014 $taro holding a conference call Monday am. They never hold conference calls.
— NathanAaron (@NathanAhron) November 7, 2014 $OXGN initiated with a BUY and $6.50 Price Target. I bought some here for a bounce.
— Rick (@Skipjackrick) November 7, 2014 I've learned... it's VERY hard to get device/drugs approved on first try with FDA $AVNR
— Shane Blackmon (@shaneblackmon) November 7, 2014 $CLVS @WilliamGerber1 Thanks for clarifying. Still haven't listened to the CC. Much better than "horrendous" but still concerning
— j l (@lomu_j) November 7, 2014 $RPRX been rocket today 47%
— MoneyEmpire (@MONEYEMPIRE) November 7, 2014 @daviesbj @analystwire That article ended up being worth almost $1B to $AGIO. Would have gone up anyway, but definitely accelerated it.
— Brad Loncar (@bradloncar) November 7, 2014 
RSS Feed
